DURECT Corporation

The momentum for this stock is not very good. DURECT Corporation is not very popular among insiders. Tradey thinks it is not wise to invest in DURECT Corporation.

DURECT Corp. is a biopharmaceutical company, which engages in the research, development, and manufac...

News

DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference

PR Newswire DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference PR Newswire CUPERTINO, Calif...\n more…

DURECT Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St DURECT ( NASDAQ:DRRX ) Second Quarter 2024 Results Key Financial Results Revenue: US$2.17m (up 4.3% from 2Q 2023). Net...\n more…

Durect files $250M mixed securities shelf

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

DRRX Stock Earnings: Durect Beats EPS, Misses Revenue for Q2 2024

InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nDRRX stock results show that Durect beat analyst estimates for earnings per share but missed on revenue for the second quarter of...\n more…

Durect (DRRX) Reports Q2 Loss, Lags Revenue Estimates

Zacks Investment Research Durect (DRRX) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.46 per share a year ago. These figures are adjusted...\n more…